Metagenics, a global nutritional supplement company backed by Gryphon Investors, has hired Pat Smallcombe as president and CEO.

Smallcombe is a current board member at Metagenics. He has worked in the consumer healthcare industry across different business models and geographic markets, including Asia, Europe and North America. His most recent corporate role was serving as company group chairman of EMEA for Johnson & Johnson, where he led a $3.5 billion portfolio of consumer health brands. He also recently served as chairman of Sibelius Natural Products.

“The health and wellness sector is at an inflection point, with consumers worldwide seeking greater access to innovative and proven nutritional solutions to their health concerns,” comments Steve LaMonte, Metagenics executive chairman of the board. “Pat is the perfect choice to help the business capitalize on the many growth opportunities it has before it.”